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Introduction
The β4 integrin is a laminin receptor that mediates the stable 
adhesion of epithelial cells to the basal membrane (when incor-
porated in hemidesmosomes) and movement of carcinoma cells 
through the extracellular matrix (when redistributed at actin-
rich protrusions; Mercurio and Rabinovitz, 2001; Litjens et al., 
2006). These roles of β4 in modulating static or dynamic adhe-
sion and in translating positional cues into different cellular 
fates are consistent with a conventional mechanochemical ac-
tivity that has been traditionally ascribed to integrins. But, in 
addition to these properties, β4 is also endowed with an unorth-
odox function: it can be a positive regulator of the anchorage-
independent growth of neoplastic cells (Zahir et al., 2003; 
Bertotti et al., 2005; Lipscomb et al., 2005). This function is 
counterintuitive given the established notion that transformed 
cells are able to grow and survive in the absence of adhesion 
and, thus, without demanding integrin-derived signals (Guo and 
Giancotti, 2004). Nonetheless, this atypical behavior could ex-
plain the frequently observed up-regulation of β4 in human car-
cinomas (Mercurio and Rabinovitz, 2001) and suggests that β4 
overexpression could afford cells with a selective advantage for 
proliferation and survival in neoplastic contexts where tissue 
architecture and canonical cell–matrix interactions are compro-
mised (Wilhelmsen et al., 2006).
A few modes of action have been proposed to explain this 
feature. In some instances, carcinoma cells may secrete abun-
dant quantities of laminin-5, which can ligate β4 and sustain the 
expansion of nonadherent colonies through activation of a Rac–
nuclear factor κB antiapoptotic pathway (Zahir et al., 2003). 
Alternatively, the expression of β4 is accompanied by the trans-
lational up-regulation of VEGF, which can act as a survival fac-
tor favoring colony formation (Lipscomb et al., 2005). Finally, 
we have recently demonstrated that β4 can promote anchorage-
independent growth in response to activation of the Met recep-
tor for hepatocyte growth factor (HGF; Bertotti et al., 2005). 
This activity does not rely on laminin engagement, as it is 
retained by a β4 truncated variant devoid of most of the extra-
cellular domain and requires Met-dependent tyrosine phosphor-
ylation of the β4 cytoplasmic domain. However, the signaling 
pathway regulating this laminin-independent activity remains to 
be elucidated. Using biochemical, pharmacological, and genetic 
approaches, we found that the Met-mediated phosphorylation 
of β4 initiates a previously unexplored transduction pathway 
that involves Shp2 recruitment, Src activation, and Gab1 phos-
phorylation and ultimately leads to dedicated stimulation of the 
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espite being a cell–matrix adhesion molecule, β4 
integrin can prompt the multiplication of neoplastic 
cells dislodged from their substrates   (anchorage-
independent growth). However, the molecular events under-
lying this atypical behavior remain partly unexplored. 
We found that activation of the Met receptor for hepato-
cyte growth factor results in the tyrosine phosphoryla-
tion of β4, which is instrumental for integrin-mediated 
  recruitment of the tyrosine phosphatase Shp2. Shp2 bind-
ing to β4 enhances the activation of Src, which, in turn, 
phosphorylates the multiadaptor Gab1 predominantly on 
consensus sites for Grb2 association, leading to privileged 
stimulation of the Ras–extracellular signal-regulated kinase 
(ERK) cascade. This signaling axis can be inhibited by 
small interfering RNA–mediated β4 depletion, by a β4 
mutant unable to bind Shp2, and by pharmacological 
and genetic inhibition of Shp2 or Src. Preservation of the 
β4 docking sites for Shp2 as well as the integrity of Shp2, 
Src, or ERK activity are required for the β4-mediated in-
duction of anchorage-independent growth. These results 
unravel a novel pathway whereby β4 directs tyrosine 
kinase–based signals toward adhesion-unrelated outcomes.
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MAPK/extracellular signal-regulated kinase (ERK) cascade. 
These results substantiate the crucial role of β4 in epithelial tu-
morigenesis and describe a novel integrin-dependent signaling 
pathway that could be exploited by growth factor receptors for 
the implementation of oncogenic responses.
Results
𝗃4 integrin recruits the tyrosine 
phosphatase Shp2
We previously demonstrated that the β4 cytodomain can be 
  tyrosine phosphorylated by Met. This event potentiates HGF-
  mediated cellular invasion through the stimulation of Ras and 
PI3K (Trusolino et al., 2001) and enhances anchorage-independent 
growth through still uncharacterized mechanisms (Bertotti et al., 
2005). Although the signals implicated in Met/β4-dependent 
cell invasion also play a crucial role in cellular proliferation and 
are likely to contribute to β4-mediated anchorage-independent 
growth, the involvement of additional transduction pathways 
cannot be excluded.
To begin to explore new signaling circuits potentially con-
trolled by β4 activity, we performed a progressive tyrosine/ 
phenylalanine mutagenesis along the β4 tail and mapped three 
tyrosines (Tyr1257, Tyr1440, and Tyr1494) that, when sequen-
tially mutated into phenylalanines, cause a gradual reduction in 
β4 phosphotyrosine content up to complete abrogation (Bertotti 
et al., 2005). Interestingly, an in silico analysis of the sequences 
surrounding these tyrosines revealed common structural fea-
tures (Fig. 1 A): Tyr1257 and Tyr1494 are both located within 
immune T cell inhibitory motifs that have been characterized as 
canonical binding regions for protein and lipid phosphatases, 
including the SH2-containing tyrosine phosphatase Shp2; simi-
larly, Tyr1440 is embedded in a degenerated consensus for 
Shp2. Based on these observations, we hypothesized that 
Tyr1257, Tyr1440, and Tyr1494 might be collectively involved 
in central signaling functions whose trait of union is multiple 
binding for Shp2.
To investigate this issue, we initially tested the potential 
association between β4 and Shp2 using an overexpression system 
(Fig. 1, B, C, and E). COS-7 cells were transiently transfected 
with the following: (1) the wild-type forms of Met and β4, 
a condition in which Met overexpression results in elevated 
tyrosine phosphorylation of the integrin; (2) wild-type β4 and 
a kinase-inactive variant of Met (Met
K−), which is unable to 
phosphorylate the integrin; (3) wild-type Met and β4 mutants 
bearing single (β4-∆Shp2
S), double (β4-∆Shp2
D), or triple 
(β4-∆Shp2
T) phenylalanine substitutions of the three critical 
tyrosines, with the consequent progressive reduction of β4 tyro-
sine phosphorylation levels (Fig. 1, B and D); and (4) wild-type 
β4 alone or wild-type Met alone as negative controls.
First, we examined direct interaction in vitro between β4 
and Shp2 in far-Western analysis using a GST fusion protein 
of the Shp2 N-terminal SH2-containing domain (GST-Shp2). 
This probe recognized β4 immunoprecipitates when the integrin 
was fully phosphorylated by activated Met but not when Met-
dependent phosphorylation was inhibited (Fig. 1 B). Association 
between GST-Shp2 and β4 was gradually weaker when using 
the single and double β4 mutants and was totally prevented 
upon expression of the β4 triple mutant (Fig. 1 B), indicating 
that all of the putative consensus sites for Shp2 are involved 
in this interaction. Notably, the effi  cacy of Shp2 binding paral-
leled the extent of β4 phosphorylation, suggesting that the 
tyrosines involved in Shp2 recruitment contain the bulk of 
the integrin substrate capacity for Met (Fig. 1 B). Tyrosine 
phosphorylation of β4 as well as Shp2 binding could not be ob-
served in the   absence of transfected Met (Fig. 1 B). Similarly, 
the transfection of Met alone was ineffective because COS-7 
cells do not express endogenous α6β4 (Niessen et al., 1997). 
When Tyr1257 and Tyr1494 were mutated into phenylalanines, 
the overall phosphotyrosine content of β4 partially decreased, 
and β4–Shp2 interaction was less effi  cient; however, the com-
plete abolition of β4 phosphorylation and Shp2 association was 
obtained only upon the phenylalanine permutation of Tyr1440 
(Fig. 1 B). Thus, in principle, Tyr1440 could autonomously 
  account for all of the observed binding events. To rule out this 
possibility, we repeated the far-Western experiment using a β4 
mutant bearing a single phenylalanine substitution of Tyr1440 
(β4-Y1440F). In COS-7 cells overexpressing Met and β4-
Y1440F, the tyrosine phosphorylation of β4 and interaction be-
tween β4 and Shp2 were reduced but not abolished (Fig. 1 C). 
This indicates that Tyr1440 is necessary but not suffi  cient for 
Shp2 association and that Tyr1257 and Tyr1494 display a resid-
ual binding activity for the phosphatase.
Next, we analyzed association in vivo by coimmunopre-
cipitation experiments in COS-7 cells overexpressing Shp2 and 
the various forms of Met and β4. Met has been reported to as-
sociate with both Shp2 (Fixman et al., 1996) and β4 (Trusolino 
et al., 2001). Therefore, it may act as a bridging molecule be-
tween the integrin and the phosphatase. To exclude this possi-
bility and assess a direct interaction between β4 and Shp2, we 
exploited a Met variant (Met
D) that retains full catalytic activity 
(therefore, it is still able to phosphorylate β4) but contains phe-
nylalanine substitutions of Tyr1349 and Tyr1356, which re-
present the docking residues for several signal transducers, 
including Shp2 (Ponzetto et al., 1994; Fixman et al., 1996; 
Furge et al., 2000). This mutant was validated for its inability to 
bind Shp2 (Fig. 1 D) and for its capacity to phosphorylate β4 
(Fig. 1 E) upon transient transfection in COS-7 cells. Under 
these conditions, Shp2 could be effi  ciently recovered in β4 im-
munoprecipitates. Conversely, the interaction was abolished in 
the absence of β4 phosphorylation or in the presence of the β4 
triple mutant displaying complete substitution of the critical 
tyrosines and was progressively diminished in the single and 
double mutants (Fig. 1 E). Again, the effi  ciency of the β4–Shp2 
interaction paralleled the extent of β4 phosphorylation; no tyro-
sine phosphorylation of β4 nor association with Shp2 could be 
detected when β4 or Met were transfected individually (Fig. 1 E).
Finally, we assessed whether tyrosine-phosphorylated β4 
can also recruit Shp2 in cells expressing endogenous proteins. 
Accordingly, we set up coimmunoprecipitation experiments in 
GTL16 cells, which express a constitutively active form of Met, 
and in FG2 cells, in which Met phosphorylation is inducible by 
HGF. Indeed, the association of Shp2 with β4 could be detected 
basally in GTL16 (Fig. 1 F) and only after ligand stimulation in β4 INTEGRIN STIMULATES SHP2–SRC SIGNALING • BERTOTTI ET AL. 995
Figure 1. Tyrosine-phosphorylated  𝗃4 interacts with Shp2. (A) Schematic representation of β4 structure. The cytoplasmic domain contains two pairs of 
type III ﬁ  bronectin-like repeats (FNIII) separated by a connecting segment (CS). The consensus sequences for Shp2 and tyrosine positions are indicated. TM, 
transmembrane domain. (B) β4–Shp2 association by far-Western analysis. COS-7 cells were cotransfected with wild-type (WT) or kinase-dead (K
−) Met 
and with wild-type β4 or β4 mutants bearing single (β4-∆Shp2
S; Y1257F), double (β4-∆Shp2
D; Y1257F and Y1494F), and triple (β4-∆Shp2
T; Y1257F, 
Y1440F, and Y1494F) phenylalanine substitutions of the potential docking tyrosines for Shp2. Lysates from each experimental point were subdivided into 
two aliquots and immunoprecipitated (IP) in parallel with antibodies to β4; Western blots (WB) were probed with antiphosphotyrosine (P-Tyr) antibodies 
(left) or with a GST-Shp2 fusion protein followed by anti-GST antibodies (right). The blots were then reprobed with anti-β4 antibodies. A fraction of the 
lysates (1/50) was loaded to detect Met from total extracts. In COS-7 cells, exogenous Met is expressed as both the precursor (top band) and mature 
form (bottom band). The weak band observable in the sixth lane corresponds to endogenous Met. (C) A β4 mutant with a single phenylalanine permutation 
of Tyr1440 (β4-Y1440F) displays reduced but detectable tyrosine phosphorylation and can bind Shp2 in far-Western analysis. (D) Coimmunoprecipitation 
experiment showing that wild-type Met but not a Met mutant with phenylalanine substitutions of the two tyrosines of the multidocking site (Met
D) associates 
with Shp2. (E) Coimmunoprecipitation of β4 and Shp2 from lysates of COS-7 cells overexpressing Shp2 and the indicated forms of Met and β4. (F and G) 
Coimmunoprecipitation of β4 and Shp2 in cells with the endogenous expression of both proteins. (F) Reciprocal coimmunoprecipitation experiment 
in GTL16 cells. Cell lysates were immunoprecipitated with antibodies to myc (negative control), Shp2 (positive control), or β4. Blots were probed with anti-
bodies against Shp2 (top), β4 (middle), or phosphotyrosine (P-Tyr; bottom). Shp2 is present in β4 immunoprecipitates (top), and β4 is present in Shp2 
immunoprecipitates (middle). Immunopuriﬁ  ed  β4 and Shp2-associated β4 appear to be constitutively tyrosine phosphorylated. (G) FG2 cells were 
either left untreated or were treated with 100 ng/ml HGF for 10 min. Lysates were immunoprecipitated with antibodies to myc or β4, and blots were probed 
as   indicated. Shp2 can be recovered from β4 immunoprecipitates after HGF stimulation (top). Treatment with HGF induces the tyrosine phosphorylation 
of β4 (bottom).JCB • VOLUME 175 • NUMBER 6 • 2006  996
FG2 cells (Fig. 1 G). The binding between tyrosine- phosphorylated 
β4 and Shp2 is specifi  c, as no coimmunoprecipitation of Shp2 
was observed with antibodies against an unrelated myc antigen 
(Fig. 1, F and G). As expected, β4 tyrosine phosphorylation was 
constitutive in GTL16 cells and was induced by HGF in FG2 
cells (Fig. 1, F and G).
Association between 𝗃4 and Shp2 leads 
to increased phosphorylation of Gab1 
through a Src-dependent mechanism
Translocation of Shp2 at the plasma membrane is essential for 
its function (Neel et al., 2003); therefore, the interaction of Shp2 
with the intracellular domain of β4 is likely to stimulate Shp2-
dependent transduction pathways. One of the best-documented 
activities of Shp2 relies on its ability to stimulate Src catalysis 
by controlling Csk recruitment (Ren et al., 2004; Zhang et al., 
2004). This notion, together with the established observation 
that Src can promote anchorage-independent growth when ab-
errantly activated (Yeatman, 2004), prompted us to investigate 
whether the signaling contribution of β4 to this process could 
entail the stimulation of Src.
To explore this subject, we examined the activation of Src 
in MDA-MB-435 breast carcinoma cells, which do express Met 
but are devoid of β4, and their counterpart cells stably trans-
fected with a human β4 cDNA (MDA-MB-435–β4 cells; Fig. 
2 A). Under basal conditions, Src enzymatic function was already 
higher in β4 cells compared with mock cells, possibly as a re-
sult of residual Met-based β4 signaling or to adhesion-triggered 
Src stimulation as previously demonstrated (Dans et al., 2001; 
Gagnoux-Palacios et al., 2003). This priming favored the fur-
ther activation of Src in response to HGF; indeed, ligand stimu-
lation led to a rapid boost of Src activity in β4 cells, whereas the 
HGF-dependent activation of Src in mock cells displayed slower 
kinetics and weaker intensity (Fig. 2 B). To evaluate whether 
the stronger and accelerated activation of Src in β4-expressing 
cells is caused by the integrin ability to bind Shp2, we generated 
MDA-MB-435 transfectants expressing the β4 triple variant 
that is unable to bind Shp2 (hereafter referred to as β4
∆Shp2). 
This mutant was exposed at the cell surface as effi  ciently as 
wild-type β4 together with the endogenous α6 subunit (Fig. 2 A). 
In line with our hypothesis, disruption of the association be-
tween β4 and Shp2 almost abolished the HGF-dependent acti-
vation of Src (Fig. 2 B). Interestingly, the β4
∆Shp2 mutant affected 
the stimulation of Src more potently than the simple absence 
of β4, suggesting that this variant could not only behave as 
a signaling-dead molecule but also as a dominant repressor 
of other endogenous β4 signaling partners. Accordingly, β4 
has been shown to impinge on signals emanating from the 
Ron tyrosine kinase receptor (Santoro et al., 2003), the EGF 
receptor (Mainiero et al., 1996; Rabinovitz et al., 1999), Erb-B2 
(Gambaletta et al., 2000; Guo et al., 2006), and tetraspanins 
(Yang et al., 2004).
Next, we searched for a Src substrate that could be a po-
tential target of this Met–β4–Shp2 signaling pathway. The Gab1 
multiadaptor protein is the major Met substrate (Birchmeier 
et al., 2003) and can also be phosphorylated by Src (Chan et al., 
2003). To verify whether the activation of Src in β4-expressing 
cells supports a more effi  cient phosphorylation of Gab1 in 
  response to HGF, we analyzed Gab1 phosphorylation levels upon 
HGF stimulation in mock and β4 cells. In time-course experi-
ments, the HGF-induced phosphorylation of Gab1 was more 
intense and durable in β4 than in mock cells (Fig. 2 C). The in-
creased phosphorylation of Gab1 in β4 cells likely depends on 
Shp2 recruitment; indeed, the HGF treatment of cells express-
ing the β4
∆Shp2 mutant led to a less effi  cient phosphorylation of 
Gab1 compared with cells expressing wild-type β4 (Fig. 2 C). 
Likewise, stimulation with increasing amounts of HGF pro-
duced a weak dose-dependent curve of Gab1 phosphorylation 
in mock cells. Conversely, Gab1 phosphorylation in β4 cells 
reached a plateau at a very low concentration of ligand, and 
the overall phosphorylation levels were more robust than in 
mock transfectants (Fig. 2 D). Again, the response of β4
∆Shp2 
cells was similar or even lower than that showed by mock 
cells (Fig. 2 D).
In a complementary approach, we abated β4 levels by len-
tiviral delivery of siRNA in MDA-MB-231 breast carcinoma 
cells, which endogenously synthesize both Met and the integrin 
(Fig. 2 E). We then reestablished β4 expression in β4-defi  cient 
cells using a siRNA-resistant variant that lacks most of the ex-
tracellular portion, including the siRNA target region, but re-
tains the ability to transduce Met-dependent responses (β4
∆extra; 
Trusolino et al., 2001; Bertotti et al., 2005). In addition to wild-
type β4
∆extra, which displays an intact cytoplasmic domain, we 
also expressed a β4
∆extra mutant with phenylalanine substitu-
tions of the tyrosines involved in Shp2 binding (Fig. 2 E). In all 
cases, Met expression was unaffected (Fig. 2 E). Consistent with 
that observed in MDA-MB-435 cells, β4 knockdown in MDA-
MB-231 resulted in the reduced HGF-dependent  phosphorylation 
of Gab1, whereas the rescue of β4 expression was accompa-
nied by the restoration of higher Gab1 phosphorylation levels 
in the presence of a signaling-competent   cytoplasmic portion 
but not when Shp2 recruitment was abolished (Fig. 2 F).
If Shp2 and Src specifi  cally contribute to Gab1 phospho-
tyrosine content in a β4-dependent manner, the attenuation of 
Shp2 and/or Src activity should affect the HGF-triggered phos-
phorylation of Gab1 only in cells expressing β4. In fact, Shp2 
inhibition by expression of a catalytically inactive dominant 
interfering isoform (Shp2
DN) resulted in the decreased phos-
phorylation of Gab1 in MDA-MB-435–β4 cells but not in mock 
cells (Fig. 2 G). Similar results were obtained when mock and 
β4 cells were treated with the Src pharmacological inhibitor 
PP2 (Fig. 2 H) or upon transfection of a kinase-dead variant of 
Src (Src
DN; Fig. 2 I).
𝗃4-dependent activation of Src leads to the 
selective association of Gab1 with Grb2
Gab1 is a scaffolding adaptor that associates with a variety 
of signal transducers after phosphorylation on multiple sites 
(Gu  and Neel, 2003). We wondered whether the Src-dependent 
increase of Gab1 phosphorylation in β4 cells leads to a generic, 
quantitative enhancement of the overall Gab1 phosphotyro-
sine content or to a selective, qualitative phosphorylation of 
defi  ned tyrosine residues with consequent specifi  c binding to 
a given transducer.β4 INTEGRIN STIMULATES SHP2–SRC SIGNALING • BERTOTTI ET AL. 997
Figure 2. Association  between  𝗃4 and Shp2 leads to the increased phosphorylation of Gab1 through a Src-dependent mechanism. (A) Expression of β4 
or the β4 mutant unable to bind Shp2 (β4
∆Shp2) in MDA-MB-435 cells. Both molecules are exposed at the cell surface, as assessed by surface biotinylation 
(top), and are expressed at comparable levels, as shown in total cell extracts (middle). Equal loading was veriﬁ  ed by probing the blot with antiactin antibod-
ies (bottom). Surface biotinylation detects the entire α6β4 integrin complex. (B) In vitro kinase assay measuring Src activation upon stimulation with 
100 ng/ml HGF at different time points in mock (blue), β4 (green), and β4
∆Shp2 (red) MDA-MB-435 cells. Data are the means ± SEM (error bars) of ﬁ  ve 
inde  pendent experiments performed in duplicate. (C) Differential Gab1 phosphorylation upon HGF stimulation for different times in mock, β4, and β4
∆Shp2 
cells. MDA-MB-435 transfectants were stimulated with 50 ng/ml HGF, and lysates were immunoprecipitated and probed as indicated. Dotted lines indicate 
the grouping of images from different parts of the same gel. Gab1 phosphorylation was quantitated by densitometric analysis (OD) relative to Gab1 protein 
content in immunoprecipitates. (D) Differential Gab1 phosphorylation upon stimulation with different doses of HGF for 30 min in mock, β4, and β4
∆Shp2 
cells. (E) Western blot analysis showing β4 expression in lysates from MDA-MB-231 cells infected with a scrambled (ctr) siRNA or with a β4-speciﬁ  c siRNA; 
β4 siRNA cells were reinfected with wild-type β4
∆extra or with a ∆Shp2 mutant. In all transfectants, Met expression was unaffected. (F) Differential Gab1 
phosphorylation in the different MDA-MB-231 transfectants. (G–I) Inhibition of Shp2 and Src impairs the HGF-dependent phosphorylation of Gab1 in MDA-
MB-435–β4 but not in mock cells. Cells were transiently transfected with a control vector (empty) or with catalytically inactive isoforms of either Shp2 
(Shp2
DN; G) or Src (Src
DN; I).The exogenous expression of Shp2 and Src is shown in the bottom panels (G and I). In H, cells were pretreated with 5 μM 
PP2 for 30 min. The PP2-mediated inhibition of Src was assessed with an antibody against active Src (bottom; H). HGF was given at 50 ng/ml for 30 min.JCB • VOLUME 175 • NUMBER 6 • 2006  998
To investigate this issue, we overexpressed Gab1 in the 
various MDA-MB-435 transfectants and assessed the ability of 
Gab1 to form supramolecular complexes with a representative 
panel of SH2-containing signaling molecules, including Grb2, 
Shc, PI3K, and Shp2 itself. Among these signaling effectors, 
Grb2 appeared to bind Gab1 more effi  ciently in β4 versus mock 
cells after HGF stimulation (Fig. 3 A). This binding was re-
duced in cells expressing the β4
∆Shp2 mutant (Fig. 3 B); simi-
larly, the PP2-mediated inhibition of Src, which decreases 
HGF-induced Gab1 phosphorylation only in β4 cells, impaired 
the association of Grb2 with Gab1 in the presence but not in the 
absence of β4 (Fig. 3 B).
Grb2 can bind tyrosine-phosphorylated Gab1 using the 
SH2 domain, but it also combines with Gab1 in a  phosphorylation-
independent manner using the SH3 domain (Holgado-Madruga 
et al., 1996). To verify that the increased association between 
Gab1 and Grb2 in β4 cells is in fact caused by the enhanced 
HGF-dependent phosphorylation of the Gab1 tyrosines respon-
sible for SH2-mediated Grb2 binding, we performed a far-
  Western analysis using a GST fusion protein of the Grb2 SH2 
domain (GST-SH2-Grb2). In accordance with the coimmuno-
precipitation data, the interaction between GST-SH2-Grb2 and 
Gab1 after HGF stimulation was much more effi  cient in β4 
cells. Again, binding was decreased in cells expressing the 
β4
∆Shp2 mutant, and treatment with PP2 impaired Gab1–Grb2 
association in β4 transfectants but not in mock cells (Fig. 3 C). 
Together, these results indicate that the Shp2-mediated activa-
tion of Src in β4 cells leads to the dedicated phosphorylation 
of Gab1 on tyrosine residues specifi  cally responsible for Grb2 
binding, a preferential association that can be abrogated by un-
coupling β4 from Shp2 or by hindering Src function. Privileged 
interaction between Gab1 and Grb2 in β4 cells results in the 
  increased stimulation of Ras-dependent effectors: indeed, the 
amplitude and persistence of ERK/MAPK activation after HGF 
stimulation were higher in β4 compared with mock and β4
∆Shp2 
transfectants (Fig. 3 D).
Shp2 and Src are required to promote 
𝗃4-mediated anchorage-independent growth
To verify whether the aforementioned signaling pathway is in 
fact responsible for the ability of β4 to promote anchorage-
  independent growth, we performed soft agar assays on several 
different MDA-MB-435 transfectants (Figs. 2 E and 4 A). As 
expected, the ectopic expression of β4 considerably enhanced 
the basal and HGF-stimulated formation of suspended colonies 
compared with mock cells both in absolute numbers (Fig. 4 B, 
graph) and in size (Fig. 4 B, images). Analogous results were 
obtained upon transfection of the β4
∆extra variant, further vali-
dating the role of this nonadhesive mutant as an effi  cient substi-
tute of wild-type β4 in HGF-driven responses and confi  rming 
the notion that the Met-dependent signaling activity of β4 does 
not require laminin ligation (Fig. 4 B; Trusolino et al., 2001; 
Bertotti et al., 2005). In contrast, expression of the β4
∆Shp2 
signaling-dead mutant was less effective, indicating that the 
Figure 3.  𝗃4-dependent activation of Src 
leads to the selective association of Gab1 with 
Grb2 and to the increased activation of ERK/
MAPKs. (A) HGF stimulation results in the in-
creased association of Gab1 with Grb2 in β4 
cells. MDA-MB-435 mock and β4 cells were 
transiently transfected with Gab1 and stimu-
lated with 100 ng/ml HGF for 30 min. Lysates 
were immunoprecipitated with antibodies to 
Gab1, and blots were probed as indicated. 
Densitometric analysis of the blots obtained 
in four experiments indicates that the HGF-
  dependent association of Grb2 with Gab1 in 
mock cells is increased 1.26-fold (± 0.48) 
compared with nonstimulated cells, whereas 
the HGF-dependent association of Gab1 with 
Grb2 in β4 cells is increased 4.7-fold (± 0.98; 
P < 0.01). (B) Abrogation of Shp2 binding or 
Src inhibition with PP2 impairs the coimmuno-
precipitation of Gab1 with Grb2 in β4 cells. 
Dotted lines indicate the grouping of images from 
different parts of the same gel. (C) Far-Western 
analysis showing the association between 
immunoprecipitated Gab1 and GST-SH2-Grb2. 
In accordance with the coimmunoprecipitation 
data, HGF-dependent Gab1–Grb2 interaction 
is increased in β4 cells compared with mock 
and β4
∆Shp2 transfectants. PP2-mediated inhibi-
tion of Src results in decreased Gab1–Grb2 in-
teraction in β4 but not in mock cells. (D) HGF 
activates ERK/MAPKs longer and more efﬁ  -
ciently in β4 cells than in mock or β4
∆Shp2 cells. 
Cells were treated with 100 ng/ml HGF for the 
indicated times, and total lysates were probed 
on blots as indicated. Band intensities were 
quantitated by densitometric analysis with 
respect to total protein content.β4 INTEGRIN STIMULATES SHP2–SRC SIGNALING • BERTOTTI ET AL. 999
interaction between β4 and Shp2 is critical for this process 
(Fig. 4 B). Transfection of dominant-negative isoforms of 
Shp2 or Src in β4-expressing cells (Fig. 4 B) as well as 
treatment of β4 cells with the Src inhibitor PP2 or with the 
ERK inhibitor PD98059 (Fig. 4 C) potently impaired HGF-
dependent clonogenic activity in soft agar. Together, these 
results reinforce the observation that Shp2, Src, and ERKs 
are central downstream transducers of β4-driven anchorage-
independent growth.
In a complementary way, siRNA-mediated reduction of 
β4 expression in MDA-MB-231 cells led to an almost complete 
abolition of basal and HGF-stimulated anchorage-independent 
growth. Colony-forming ability was partially reestablished 
upon the expression of the β4
∆extra siRNA-resistant variant dis-
playing a wild-type intracellular domain but not upon expres-
sion of the ∆Shp2 mutant (Fig. 5).
Discussion
When a normal cell of epithelial origin happens to lose contact 
with the basement membrane, the surrounding stromal com-
partment impedes its multiplication and, in the meantime, stim-
ulates its apoptotic elimination (Frisch and Screaton, 2001). 
To avoid this and to ensure successful metastatic dissemination, 
malignant elements undergo an adaptive process  that relies 
mainly on two strategies. One is the abnormal and unpolarized 
secretion of basement membrane molecules, which aberrantly 
reconstitute the original histological niche, thus imparting sur-
rogate proliferative and survival signals. Parallel (or alternative) 
to this is the hyperactivation of oncogenic pathways, which pro-
duce a global amplifi  cation of the cell signaling activity with 
consequent elusion of the external adhesive consensus (Hanahan 
and Weinberg, 2000). Whatever the mechanism used, the 
Figure 4.  𝗃4 sustains HGF-induced anchorage-
independent growth through the activation 
of Shp2, Src, and ERK. (A) Western blot analy-
sis showing expression of the indicated cDNAs 
in MDA-MB-435 cells subjected to soft agar 
assays. Filters probed with anti-Shp2 and -Src 
antibodies were deliberately underexposed 
to better visualize the overexpression of exog-
enous proteins. (B) Representative images and 
quantitation of soft agar assays in MDA-
MB-435 cells with ectopic expression of the 
indicated proteins in the absence (NS) or 
  presence of 30 ng/ml HGF. Pictures show col-
ony aspect at high magniﬁ  cation, whereas the 
graph   reports colony numbers as counted at 
low magniﬁ  cation over the entire microscopic 
ﬁ   eld. Light bars, no stimulation; dark bars, 
HGF. (C) Representative images and quantita-
tion of soft agar assays in MDA-MB-435 cells 
expressing β4 that were either left untreated 
(NS) or were treated with HGF in the absence 
or presence of the Src inhibitor PP2 or the ERK 
inhibitor PD98059. Data are the means ± 
SEM (error bars) of two independent experiments 
performed in triplicate. **, P < 0.01 with   respect 
to all other transfectants. Bars, 400 μm.JCB • VOLUME 175 • NUMBER 6 • 2006  1000
  phenotypic outcome of this process is that neoplastic cells ac-
quire the ability to grow in the absence of proper anchorage.
In this study, we show that the β4 integrin conspires with 
the tyrosine kinase Met for effi  cient execution of anchorage-
  independent growth by channeling Met signals toward activa-
tion of the Ras-ERK oncogenic cascade. This function relies on 
Met-triggered phosphorylation of the β4 cytoplasmic domain 
and on the ensuing recruitment of the tyrosine phosphatase 
Shp2 to the integrin tail. β4–Shp2 association results in the 
stimulation of Src, which, in turn, favors a more effi  cient phos-
phorylation of the Gab1 multiadaptor protein, mainly on tyro-
sines involved in Grb2 binding. Ultimately, privileged interaction 
between Gab1 and Grb2 leads to dedicated stimulation of the 
MAPK–ERK pathway.
Structural aspects of 𝗃4–Shp2 interaction
Association between β4 and Shp2 depends on the integrity of 
three tyrosines along the β4 cytoplasmic domain (Tyr1257, 
Tyr1440, and Tyr1494) that are inserted in canonical or degene-
rated motifs for the SH2 domain of Shp2 and, consequently, 
could act as docking sites for the phosphatase when phosphory-
lated. However, based on the crystal structure of a fragment of 
the β4 intracellular portion encompassing the fi  rst pair of type 
III fi  bronectin-like (FNIII) repeats (de Pereda et al., 1999), in-
teraction between Shp2 and Tyr1257 appears to be more com-
plicated because this tyrosine is part of the hydrophobic core of 
the second repeat (Fig. 1 A). Thus, it may not be easily accessi-
ble for phosphorylation because of conformational constraints.
This information is in disagreement with our fi  ndings and 
with a previous study showing the phosphorylation of Tyr1257 
in response to the antibody-mediated ligation of β4 (Shaw, 
2001). A possible explanation for this discrepancy is that al-
though the aromatic ring of Tyr1257 is in fact involved in hy-
drophobic interactions with other residues and is not accessible 
to the solvent, the side chain is not completely buried in the 
FNIII core so that the OH group reaches the solvent-accessible 
surface of the protein. This kind of spatial organization seems 
to be permissive for phosphorylation; for example, the human 
Vaccinia H1-related phosphatase is phosphorylated by ZAP-70 
at Tyr138 despite that only the OH group of the amino acid is 
partially exposed to the solvent (Alonso et al., 2003). Moreover, 
physical association with Met could affect the structural organi-
zation of β4 and induce a more relaxed conformation of the 
FNIII repeat, facilitating recognition by the kinase and transfer 
of the phosphate group.
In any case, our observation that the phenylalanine per-
mutation of Tyr1257 results in reduction of the overall β4 phos-
photyrosine content and in a less effi  cient association with Shp2 
does not exclude the possibility that Tyr1257 is not a direct 
phosphorylation site, but it is necessary for the phosphoryla-
tion of other residues that, in turn, could be involved in Shp2 
  recruitment. This hypothesis is in agreement with the general 
notion that bindings between SH2 domains and the correspond-
ing ligand motifs hardly occur in rigid structural environments 
such as the FNIII fold.
A novel signaling pathway connecting 
𝗃4 integrin to ERK activation: biochemical 
and biological insights
The importance of the signaling axis explored here in β4-
  mediated anchorage-independent growth is underscored by the ob-
servations that a β4 mutant unable to bind Shp2 cannot sustain 
this process and that interference with Shp2, Src, or ERK im-
pairs the biological activity of wild-type β4. Interestingly, Shp2 
is known to act downstream from Met when physically associ-
ated with Gab1 to sustain the prolonged stimulation of ERKs 
(Maroun et al., 2000). However, the signaling intermediates pro-
pagating this activity remain elusive (Gu and Neel, 2003). Our 
fi  ndings confi  rm the crucial role of Shp2 as a positive regulator 
of Ras-dependent signals in response to HGF and provide an al-
ternative pathway as well as several additional molecular actors 
that connect Met function to the enhancement of ERK activity.
The unorthodox observation that β4 contributes to the 
malignant phenotype by acting as a biochemical selector of tu-
morigenic signaling pathways unveils an unforeseen function 
that transcends the activity of β4 as an integrin and assimilates 
it to classical signal relay adapters endowed with oncogenic 
Figure 5.  𝗃4 sustains HGF-induced anchorage-independent growth 
through the recruitment of Shp2. Representative images and quantitation of 
soft agar assays in MDA-MB-231 cells displaying the artiﬁ  cial manipula-
tion of β4 levels as shown in Fig. 2 E. Data are the means ± SEM (error bars) 
of two independent experiments performed in triplicate. **, P < 0.01 with 
respect to all other transfectants. WT, wild type. Bar, 400 μm.β4 INTEGRIN STIMULATES SHP2–SRC SIGNALING • BERTOTTI ET AL. 1001
  potential. Something similar has been described for β1A integ-
rin, the most widely expressed spliced isoform of β1 integrins: 
in this case, interaction between β1A and the insulin-like growth 
factor-I tyrosine kinase receptor results in integrin-mediated re-
cruitment of the downstream effector IRS1, which inhibits cell 
adhesion and stimulates insulin-like growth factor–dependent 
cellular proliferation and tumor growth (Goel et al., 2004).
Most of the signaling effectors along the transduction path-
way discussed in this study are involved in human malignancies 
in vivo: Met, β4, and Src are often overexpressed (and coex-
pressed) in a vast number of human carcinomas (Mercurio and 
Rabinovitz, 2001; Trusolino and Comoglio, 2002; Ishizawar 
and Parsons, 2004), and Shp2 gain of function mutations have 
been described in some solid tumors and in various forms of 
leukemia (Bentires-Alj et al., 2004). Gab2, a close homologue 
of Gab1, is amplifi  ed and overexpressed in a fraction of human 
breast tumors and collaborates with the ErbB2 oncogene for 
  activation of a Shp2–ERK pathway that drives mammary carci-
nogenesis (Bentires-Alj et al., 2006). Intriguingly, β4 has re-
cently been shown to cooperate with ErbB2 in breast cancer 
onset (Guo et al., 2006). Finally, constitutively active Src tran-
scriptionally up-regulates HGF in breast carcinoma cells, gen-
erating an autocrine loop that promotes cancer progression 
(Wojcik et al., 2006). Altogether, these fi  ndings suggest not 
only a functional role in vivo but also a cooperative effect and a 
potential epistatic relationship for these signals.
Finally, it is worth noting that the tyrosines involved in 
Shp2 binding represent biochemical hotspots for β4 signaling 
capacity also with respect to other transduction pathways: 
Tyr1257 is necessary for β4 phosphorylation in response to 
laminin ligation (Shaw, 2001), Tyr1440 is responsible for SH2-
mediated interaction with the Grb2 upstream effector Shc (Dans 
et al., 2001), and Tyr1494 is involved in the adhesion-driven 
stimulation of PI3K (Shaw, 2001). It will be interesting to ana-
lyze whether these additional transducers can complement or 
substitute for the signaling axis identifi  ed in this study for fos-
tering β4-mediated anchorage-independent growth and possi-
bly tumorigenesis.
Met and 𝗃4 in cancer onset and progression
Accumulating evidence suggests that the aptitude of a neoplasm 
to disseminate at distant sites is already preordained by the pro-
tein repertoire that progenitor cells express relatively early in 
tumorigenesis. This indicates that the phenotype acquired en 
route by an evolving tumor cell can confer not only a selective 
advantage for cell replication (a condition necessary for forma-
tion of the primary tumor mass) but also, later during neoplas-
tic progression, the tendency to metastasize (Bernards and 
Weinberg, 2002).
This line of thinking fi  ts nicely with our fi  ndings on the 
role of β4 and Met in tumor evolution. We and others have dem-
onstrated that both molecules, individually or in combination, 
are able to enhance the motility and survival of cancer cells as a 
prelude for neoplastic invasion and metastasis (Mercurio and 
Rabinovitz, 2001; Trusolino and Comoglio, 2002). Here, we 
show that the same molecules can also cooperate for anchorage-
independent growth, which is the experimental and phenotypic 
hallmark of primary tumorigenesis. Together, these data allow 
us to draw a linear fl  owchart along which β4 and Met are caus-
ally involved fi  rst in the derailment of cell accretion and later in 
the promotion of metastatic spread.
This dual activity of β4 and Met on epithelial cells is par-
alleled by their common ability to induce a peculiar phase of the 
angiogenic process in endothelial cells. Specifi  cally, both the 
inhibition of β4 signaling by an intracellularly truncated β4 
mutant (Nikolopoulos et al., 2004) and the inhibition of Met 
function by a decoy receptor (Michieli et al., 2004) prevent 
branching of medium- and small-size vessels into microvessels 
during intratumor vascularization, suggesting that both mole-
cules are selectively involved in the onset of the invasive step of 
pathological angiogenesis. At present, we do not know whether 
this vascular phenocopy is supported by a functional collabora-
tion between β4 and Met. However, all of these observations 
highlight the versatility of the β4–Met system in promoting the 
various and sequential aspects of neoplastic progression.
Materials and methods
Materials, antibodies, and vectors
We used the following reagents: anti–human Met, anti-Shp2, anti-Src, anti-
actin, GST-Shp2, and GST-SH2-Grb2 (Santa Cruz Biotechnology, Inc.); 
anti-β4 integrin (BD Biosciences and Chemicon); anti-Gab1, anti-Shc, anti-
PI3K, antiphosphotyrosine, and anti-GST (Upstate Biotechnology); anti-
Grb2 (Transduction Laboratories); antiactive and total ERK/MAPK (Promega); 
antiactive Src (nonphospho-Tyr529; Biosource International); PP2 (Calbio-
chem); wild-type Shp2 and catalytically inactive C/S Shp2 in pJ3H vector 
(obtained from B.G. Neel, Harvard Medical School, Boston, MA); and 
wild-type Src and kinase-dead K/R Src in pCMV5 vector (obtained from 
J. Brugge, Harvard Medical School). The β4
∆Shp2 construct containing phe-
nylalanine mutations of Y1257, Y1440, and Y1494 was generated by 
PCR ampliﬁ  cation of the BssHII–NotI fragment of a β4 template already 
containing the Y1257F and Y1494F substitutions (obtained from L.M. 
Shaw, Harvard Medical School). To create the β4 siRNA expression vector, 
oligonucleotides used by Chung et al. (2004) were annealed and ligated 
into pSUPER between the BglII and HindIII sites. BamHI- and XhoI-digested 
inserts were then subcloned into the pRLL5 lentiviral vector. A scrambled β4 
oligonucleotide was used as a control. The constructs encoding for wild-
type Met, kinase-inactive Met, wild-type β4, β4-1440F, and β4
∆extra have 
been described previously (Trusolino et al., 2001). The β4 cDNA used in 
this study corresponds to PubMed accession no. AAC51632 and matches 
with the sequence originally cloned by Suzuki and Naitoh (1990).
Cell culture, transfection, and viral infection
COS-7, MDA-MB-435, and MDA-MB-231 cells were cultured in DME 
supplemented with 10% FBS (Invitrogen). The expression of exogenous 
proteins was obtained with LipofectAMINE- or LipofectAMINE 2000 
(Invitrogen)–mediated transfection according to the manufacturer’s proto-
col or with retroviral or lentiviral infection. Viral hybrid vectors were pro-
duced by the transient transfection of 293T cells. Viral supernatants were 
ﬁ  ltered through a 0.22-μm ﬁ  lter, and infections were performed in the pres-
ence of 4 μg/ml polybrene (Sigma-Aldrich).
Biochemical methods
For immunoprecipitations, 5 × 10
6 cells were lysed for 20 min at 4°C with 
1 ml of a buffer containing 50 mM Hepes, pH 7.4, 5 mM EDTA, 2 mM 
EGTA, 150 mM NaCl, 10% glycerol, and 1% Triton X-100 in the presence 
of protease and phosphatase inhibitors. For β4–Shp2 coimmunoprecipita-
tions in FG2 cells, 1% Brij58 was used instead of Triton X-100. Extracts 
were clariﬁ  ed at 12,000 rpm for 15 min, normalized with the BCA Protein 
Assay Reagent kit (Pierce Chemical Co.), and incubated with different 
mAbs for 2 h at 4°C. Immune complexes were collected with either protein 
G– or protein A–Sepharose, washed in lysis buffer in the presence of 1 M 
LiCl, and eluted. Total cellular proteins were extracted by solubilizing 
the cells in boiling SDS buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
and 1% SDS). Extracts were electrophoresed on SDS-polyacrylamide gels 
and transferred onto nitrocellulose membranes (Hybond; GE Healthcare). JCB • VOLUME 175 • NUMBER 6 • 2006  1002
Nitrocellulose-bound antibodies were detected by the ECL system (GE 
Healthcare). Unless otherwise indicated, cells were stimulated with 50 ng/ml 
HGF for 30 min. PP2 was generally used at a 10-μM concentration and 
applied to cells for 30 min. In experiments aimed at analyzing the associa-
tion of Gab1 with signal transducers and the HGF-dependent activation of 
ERKs, mock cells and cells expressing wild-type β4 or β4
∆Shp2 were tran-
siently transfected with a Gab1 cDNA.
For far-Western analysis, membranes were blocked for 1 h in TBS, 
0.1% Tween-20, 5% BSA, and 3 μm glutathione and were incubated for 
3 h with 1 μg/ml GST fusion protein previously adsorbed to 3 μM glutathione 
in 0.5% BSA. Filters were subsequently decorated with anti-GST antibody.
Src kinase assays were performed on Src immunoprecipitates using 
a commercial kit (Upstate Biotechnology) based on the phosphorylation of 
a speciﬁ  c substrate peptide (K  V  E  K  I  G  E  G  T  Y  G  V  V  Y  K  ) using the transfer of the 
γ-phosphate of γ-[
32P]ATP by Src. The phosphorylated substrate was then 
separated from the residual γ-[
32P]ATP using phosphocellulose paper and 
quantiﬁ  ed with a scintillation counter.
Soft agar assay
3,000 cells were resuspended in complete medium containing 0.5% 
Seaplaque agar. Cells were seeded in 24-well plates containing a 1% agar 
underlay and supplemented twice a week with complete medium. In some 
experiments, MDA-MB-435–β4 cells were treated twice a week with 5 μM 
PP2 or 10 μM PD98059. Colonies were stained by the incorporation of 
tetrazolium salts 2 (for MDA-MB-435) or 3 wk (for MDA-MB-231) after 
seeding. Colonies were coded and scored in a blinded fashion by a sec-
ond observer. Colony numbers were obtained using a phase-contrast light 
microscope (DMIL; Leica) ﬁ  tted with a 32-grid eyepiece at a total magniﬁ  -
cation of 20×. Images were captured with ImageReady software (Adobe) 
using a microscope (DMIL; Leica) and a 20 × 0.30 objective (Leica) 
equipped with a digital camera (DFC320; Leica).
Statistical and densitometric analysis
Results are means ± SEM. Comparisons were made using the two-tailed 
t test. P-values <0.05 were considered to be statistically signiﬁ  cant. Blot 
images were captured using a molecular imager (ChemiDoc XRS; Bio-Rad 
Laboratories). Densitometric analysis was performed with analysis software 
(Quantity One 1-D; Bio-Rad Laboratories) installed on the imager. Images 
were arranged and labeled using Illustrator (Adobe).
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